Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ASP5354 in Healthy Adults
NCT03698305Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2018
- Primary completion
- May 2019
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pudexacianinium chloride, sponsored by Astellas Pharma. Primary endpoints: Safety and tolerability assessed by nature, frequency, and severity of Adverse Events, Number of participants with laboratory value abnormalities and/or AEs and 3 more. Started Oct 2018; status: completed.
02
Drugs
pudexacianinium chloride
Beyond the preview
Go deeper on NCT03698305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698305.